Today, a novel substance is registered every 2.3 seconds. To protect people and the environment from harm, such a massive amount of substances must be regulated and any of their potential toxic effects should be thoroughly evaluated. This poses a major challenge to the toxicology industry and, as such, it opens tremendous market opportunities. Nagi Bioscience proposes the first “organism-on-chip” platform offering in vivo data at the scale of in vitro for toxicology and drug screening purposes.